DGAP-News: aap Implantate AG / Key word(s): Capital Increase/Financing
10.05.2019 / 15:51
The issuer is solely responsible for the content of this announcement.
The information contained in this announcement is not intended for publication or distribution in or within the United States of America, Australia, Canada or Japan.
aap Implantate AG (“aap”) successfully completed the capital increase with subscription rights out of authorised capital resolved on 17 April 2019. aap‘s share capital is increased by issuing a total of 3,360,467 new no-par value bearer shares against cash contributions by EUR 3,360,467.00 from EUR 28,706,910.00 to EUR 32,067,377.00. Based on the determined subscription price of EUR 1.04 per new share the gross issuing proceeds are around EUR 3.5 million. The new shares are entitled to participate in dividends as of 1 January 2018.
“We are pleased about the successful capital increase and thank our shareholders for their trust,” says Rubino Di Girolamo, Chairman of the Management Board / CEO at aap. “We intend to use the cash inflow from the capital increase to finance our planned sales growth and the human clinical study for our pioneering and innovative silver coating technology.”
At all, 3,260,467 new shares were subscribed for by exercising subscription and oversubscription rights. They include the exercise by major existing shareholders who had committed themselves to subscribe for a total of 2,211,539 new shares ahead of the transaction. In addition, a total of 100,000 new shares, that were not subscribed for, were placed with qualified institutional investors by means of a private placement after the subscription period had expired.
With the cash inflow from the capital increase and two further external financings aap has
This announcement constitutes neither an offer nor a solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan or any other jurisdiction in which an offer is unlawful.
This announcement is not an offer of securities for sale in the United States. Securities may be offered or sold in the United States only upon prior registration or upon exemption from the obligation of prior registration pursuant to the Securities Act. If a public offering of securities were to take place in the United States, it would be effected by means of a securities prospectus which investors could obtain from the Company. This prospectus would contain detailed information about the Company and its management, as well as financial information. There will be no public offering of the securities referred to in this announcement in the United States.
Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to or for the account of persons resident in Australia, Canada or Japan.
About aap Implantate AG
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 – 134; Fax.: +49/30/750 19 – 290; firstname.lastname@example.org
10.05.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||809895|
|End of News||DGAP News Service|